BioDelivery Sciences International Inc
F:BD5
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Hormel Foods Corp
NYSE:HRL
|
US |
|
INKON Life Technology Co Ltd
SZSE:300143
|
CN |
BioDelivery Sciences International Inc
Other Receivables
BioDelivery Sciences International Inc
Other Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioDelivery Sciences International Inc
F:BD5
|
Other Receivables
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Other Receivables
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Other Receivables
$4.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
30%
|
CAGR 10-Years
15%
|
|
|
Pfizer Inc
NYSE:PFE
|
Other Receivables
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Other Receivables
$889m
|
CAGR 3-Years
10%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Other Receivables
$2.4B
|
CAGR 3-Years
13%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
|
BioDelivery Sciences International Inc
Glance View
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
See Also
What is BioDelivery Sciences International Inc's Other Receivables?
Other Receivables
0
USD
Based on the financial report for Dec 31, 2021, BioDelivery Sciences International Inc's Other Receivables amounts to 0 USD.
